Published in Expert Rev Neurother on April 01, 2008
EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol (2012) 0.91
Molecular targeting of intracellular compartments specifically in cancer cells. Genes Cancer (2010) 0.83
Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes. Int J Nanomedicine (2017) 0.75
Concurrent Chemotherapy of Malignant Glioma in Rats by Using Multidrug-Loaded Biodegradable Nanofibrous Membranes. Sci Rep (2016) 0.75
Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes. Oncotarget (2016) 0.75
The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res (2008) 2.21
Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res (2005) 2.11
EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res (2005) 2.02
IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia (2002) 1.42
Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci U S A (2002) 1.39
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A (2010) 1.29
Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res (2008) 1.28
A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther (2007) 1.27
Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Res (2008) 1.17
An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev (2007) 1.09
Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia (2004) 1.07
Ephs and ephrins in cancer: ephrin-A1 signalling. Semin Cell Dev Biol (2011) 1.06
Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. J Biol Chem (2002) 1.04
Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J Neurooncol (2003) 1.00
IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. Transl Oncol (2011) 0.93
An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol (2011) 0.91
EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol (2012) 0.91
Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol (2014) 0.91
Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biother Radiopharm (2008) 0.87
Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem (2012) 0.84
Molecular targeting of intracellular compartments specifically in cancer cells. Genes Cancer (2010) 0.83
Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. J Biol Chem (2013) 0.83
Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients. Vet Radiol Ultrasound (2013) 0.82
Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol (2014) 0.82
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia (2013) 0.81
Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. J Neurooncol (2013) 0.81
Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin. Clin Cancer Res (2009) 0.80
A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker. Neuro Oncol (2012) 0.78
Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. Am J Clin Oncol (2017) 0.77
Ephs and Ephrins in malignant gliomas. Growth Factors (2014) 0.76
Personalized, multivalent, and more affordable: the globalization of vaccines. Clin Cancer Res (2005) 0.76
Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy. BioDrugs (2012) 0.75
866 EphA2 Receptor Represents a New Marker and Therapeutic Target in Pediatric Malignancies. Neurosurgery (2005) 0.75